The ALLHAT Lipid Lowering Trial—Less Is Less

Simple item page
dc.contributor.authorPasternak, Richard C.
dc.date.accessioned2019-08-14T15:01:53Z
dc.date.available2019-08-14T15:01:53Z
dc.date.issued2002
dc.description.abstractThe Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Lipid Lowering Trial (ALLHAT-LLT),1 published in this issue of THE JOURNAL, is the second-largest lipid-lowering trial yet reported. This randomized trial, a subset of the larger ALLHAT hypertension study,2 followed up 10 355 patients (49% women) who had hypertension and were 55 years or older for a mean of 4.8 years. Patients were randomly assigned to receive 40 mg of pravastatin (open label) vs "usual care" in 513 clinical centers, the majority of which were community-based. These centers were a subset of the 623 centers that treated patients for the larger (N = 33 357) ALLHAT hypertension study.2 Despite a 28% reduction in low-density lipoprotein cholesterol (LDL-C) from baseline in the pravastatin treatment group, the trial failed to show a benefit in either the primary outcome (all-cause mortality) or the key secondary outcome (combined nonfatal myocardial infarction and . . .
dc.description.urihttp://jama.ama-assn.org/content/288/23/3042.full
dc.identifierhttps://doi.org/10.13016/bgo0-0wrc
dc.identifier.citationPasternak, Richard C. (2002) The ALLHAT Lipid Lowering Trial—Less Is Less. JAMA, 288 (23). pp. 3042-3044.
dc.identifier.otherEprint ID 1256
dc.identifier.urihttp://hdl.handle.net/1903/23101
dc.subjectPharmacotherapy
dc.subjectHypertension
dc.subjectstudies
dc.subjectlipid-lowering trial
dc.subjecthypertension study
dc.subjectpravastatin
dc.titleThe ALLHAT Lipid Lowering Trial—Less Is Less
dc.typeArticle

Files

Collections

Minority Health and Health Equity Archive